REG - Destiny Pharma PLC - Publication of XF-73 drug synergy data

Destiny PharmaAnnouncement

07/07/2022 07:17

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220707:nRSG5788Ra&default-theme=true

RNS Number : 5788R  Destiny Pharma PLC  07 July 2022

Destiny Pharma plc

("Destiny Pharma" or "the Company")

 

Destiny Pharma announces publication of XF-73 drug synergy data

 

XF-73 shown to enhance the activity of two antibacterial drugs

 

Findings may lead to improved treatments for lethal lung infections

and infected diabetic foot ulcers caused by antimicrobial resistant bacteria

 

Brighton, United Kingdom - 07 July 2022 - Destiny Pharma plc (AIM: DEST), a
clinical stage biotechnology company focused on the development of novel
products to prevent life-threatening infections, today announces the
publication of new data
(https://www.frontiersin.org/articles/10.3389/fcimb.2022.904465/full) on XF-73
with Cardiff University in Frontiers in Cellular and Infection Microbiology 1 
a peer-reviewed publication. This research project is partly funded through a
£1.6m collaboration between Destiny Pharma, Cardiff University, China Medical
Systems and University of Tianjin. The collaboration was established under the
UK-China AMR grant fund set up by Innovate UK and the Department of Health and
Social Care with the Chinese Ministry of Science and Technology.

 

These new in vitro data were generated by Dr Emma Board-Davies and Professor
David Williams at the School of Dentistry, Cardiff University, in experiments
studying the potential for XF-based drugs to enhance the effectiveness of key
antibacterial treatments - many of which are now suffering from the emergence
of bacterial resistance mechanisms. Multiple combinations of XF-based drugs
and selected antibacterials were assessed and enhanced effectiveness beyond
the action of the antibacterial drug alone was identified. The new findings
were:

 

1.    Synergistic effect when XF-73 was combined with polymyxin B, a last
resort antibacterial drug used to treat life-threatening lung bacterial
infections. The addition of XF-73 was found to enhance polymyxin B potency
against Pseudomonas aeruginosa, a top priority WHO bacterial pathogen, by
4-fold.

 

2.    Synergistic effect when XF-73 was combined with ertapenem, used to
treat infected diabetic foot ulcers (DFUs). The addition of XF-73 was found to
enhance ertapenem potency against methicillin-resistant Staphylococcus aureus
(MRSA), another top priority WHO bacterial pathogen, by 8-fold.

 

These positive results open the way for further studies with multidrug
resistant strains of Pseudomonas aeruginosa and MRSA to progress the
combination of XF-73 with these antibacterials as potential new treatments for
serious lung and DFU infections. The new data further add to the existing
published research and clinical data relating to the XF platform and XF-73.
These data clearly demonstrate the attributes of XF-based drugs and their
significant potential to provide much needed new treatments that will prevent
and/or treat serious infections and address the global threat of antimicrobial
resistance (AMR).

 

Dr Bill Love, Chief Scientific Officer of Destiny Pharma, stated: "These
latest data emerging from the highly successful InnovateUK, China AMR XF-based
drug project have identified new opportunities to deliver better treatments
for lung and DFU infections by using XF-73 alongside established antibacterial
drugs. The addition of XF-73 significantly enhances the potency of these
approved antibacterial drugs, which should improve their ability to treat such
infections. We will be exploring the options for further research and
development to progress XF-73 in such combinations to improve the treatment of
these serious lung and DFU infections."

 

Professor David Williams, Professor of Oral Microbiology, Cardiff University,
added: "The control and management of infections involving antimicrobial
resistant microorganisms is becoming increasingly problematic and as such
there is urgent need for new and effective antimicrobials. An important
strategy that can be exploited is combinational therapy involving multiple
agents where synergistic effects are realised. This increases the efficacy of
individual agents and reduces the risk of further development of resistance."

 

For further information, please contact:

 

Destiny Pharma plc
Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440
pressoffice@destinypharma.com
(https://www.destinypharma.com/2022/05/26/26-may-2022-destiny-pharma-plc-board-changes/blank)

 

Optimum Strategic Communications
(https://www.destinypharma.com/2022/05/26/26-may-2022-destiny-pharma-plc-board-changes/blank)

Mary Clark / Manel Mateus / Eleanor Cooper

+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com
(https://www.destinypharma.com/2022/05/26/26-may-2022-destiny-pharma-plc-board-changes/blank)

 

finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

MC Services AG
Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2b clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SPOR-COV(TM), a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF- drug research projects.

 

For further information on the company, please visit www.destinypharma.com
(https://www.destinypharma.com)

 

 1  https://doi.org/10.3389/fcimb.2022.904465
(https://doi.org/10.3389/fcimb.2022.904465)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZGGNKVKGZZM